BCLI: Phase 3 ALS Data Due Soon…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL ARWR RESEARCH REPORT Business Update Topline Data from Phase 3 ALS Trial Before End of November 2020 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS) ( NCT03280056 ). A total of 200 patients were randomized 1:1 to receive NurOwn® or placebo